DK44791D0 - Behandling af beskadiget knoglemarv - Google Patents

Behandling af beskadiget knoglemarv

Info

Publication number
DK44791D0
DK44791D0 DK91447A DK44791A DK44791D0 DK 44791 D0 DK44791 D0 DK 44791D0 DK 91447 A DK91447 A DK 91447A DK 44791 A DK44791 A DK 44791A DK 44791 D0 DK44791 D0 DK 44791D0
Authority
DK
Denmark
Prior art keywords
pharmaceutically acceptable
damage
aliphatic
substituted
bone marrow
Prior art date
Application number
DK91447A
Other languages
English (en)
Other versions
DK44791A (da
Inventor
Richard F Borch
Therese K Schmalbach
Original Assignee
Univ Rochester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rochester filed Critical Univ Rochester
Publication of DK44791D0 publication Critical patent/DK44791D0/da
Publication of DK44791A publication Critical patent/DK44791A/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Polishing Bodies And Polishing Tools (AREA)
  • Magnetic Heads (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
DK044791A 1988-09-12 1991-03-12 Behandling af beskadiget knoglemarv DK44791A (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/243,405 US4938949A (en) 1988-09-12 1988-09-12 Treatment of damaged bone marrow and dosage units therefor
PCT/US1989/003941 WO1990002550A1 (en) 1988-09-12 1989-09-12 Treatment of damaged bone marrow and dosage units therefor

Publications (2)

Publication Number Publication Date
DK44791D0 true DK44791D0 (da) 1991-03-12
DK44791A DK44791A (da) 1991-05-10

Family

ID=22918655

Family Applications (1)

Application Number Title Priority Date Filing Date
DK044791A DK44791A (da) 1988-09-12 1991-03-12 Behandling af beskadiget knoglemarv

Country Status (9)

Country Link
US (1) US4938949A (da)
EP (1) EP0433393B1 (da)
JP (1) JPH04500676A (da)
AT (1) ATE119771T1 (da)
AU (1) AU623184B2 (da)
DE (1) DE68921760D1 (da)
DK (1) DK44791A (da)
NZ (1) NZ230622A (da)
WO (1) WO1990002550A1 (da)

Families Citing this family (609)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5187193A (en) * 1988-09-12 1993-02-16 University Of Rochester Method for stimulating transplanted bone marrow cells
AU6647190A (en) * 1989-10-10 1991-05-16 University Of Rochester Method for producing bone marrow growth cell factors
JPH06509578A (ja) * 1991-07-26 1994-10-27 ユニバーシティ・オブ・ロチェスター 悪性細胞利用による癌治療法
US5240914A (en) * 1992-02-03 1993-08-31 Adolph Schwimmer Method and compositions for inhibiting tumor cell metabolism
US6514949B1 (en) 1994-07-11 2003-02-04 University Of Virginia Patent Foundation Method compositions for treating the inflammatory response
US6448235B1 (en) 1994-07-11 2002-09-10 University Of Virginia Patent Foundation Method for treating restenosis with A2A adenosine receptor agonists
US7135584B2 (en) 1995-08-07 2006-11-14 Wake Forest University Lipid analogs for treating viral infections
CA2197319C (en) 1994-08-29 2009-01-27 Louis S. Kucera Lipid analogs for treating viral infections
US5767142A (en) * 1996-03-20 1998-06-16 Rutgers, The State University Of New Jersey Trisbenzimidazoles useful as topoisomerase I inhibitors
US5807874A (en) * 1995-05-17 1998-09-15 Rutgers, The State University Of New Jersey Trisbenzimidazoles useful as topoisomerase I inhibitors
US5616575A (en) * 1995-12-04 1997-04-01 Regents Of The University Of Minnesota Bioactive tricyclic ibogaine analogs
US5932553A (en) 1996-07-18 1999-08-03 The Regents Of The University Of California Illudin analogs useful as antitumor agents
US5723632A (en) * 1996-08-08 1998-03-03 Mgi Pharma, Inc. Total synthesis of antitumor acylfulvenes
US5922761A (en) * 1996-09-06 1999-07-13 Medinox, Inc. Methods for in vivo reduction of iron levels and compositions useful therefor
PL332416A1 (en) * 1996-09-23 1999-09-13 Rutgers Substituted heterocyclic compounds as anticarcinogenic agents
US5916903A (en) * 1997-02-28 1999-06-29 Synapse Pahrmaceuticals International, Inc. Method for reducing the effects of antineoplastic disease treatment
US5866558A (en) * 1997-05-08 1999-02-02 Regents Of The University Of Minnesota 6-alkynyl steroids
US6486214B1 (en) 1997-09-10 2002-11-26 Rutgers, The State University Of New Jersey Polyanhydride linkers for production of drug polymers and drug polymer compositions produced thereby
US6468519B1 (en) * 1997-09-10 2002-10-22 Rutgers, The State University Of New Jersey Polyanhydrides with biologically active degradation products
US6140328A (en) 1997-12-12 2000-10-31 Rutgers, The State University Of New Jersey Heterocyclic cytotoxic agents
DE69805975T2 (de) * 1997-12-29 2002-12-19 Research Corp. Technologies, Inc. 2-beta-substituierte-6-alkylidenpenizillansäure-derivate als beta-laktamase inhibitoren
US6432941B1 (en) * 1998-01-20 2002-08-13 Parker Hughes Institute Vanadium compounds for treating cancer
US6051603A (en) 1998-01-20 2000-04-18 Wayne Hughes Institute Vanadium (IV) metallocene complexes having sperm motility inhibiting activity
US6245808B1 (en) 1998-11-05 2001-06-12 Parker Hughes Institute Oxy-vanadium (IV) complexes having spermicidal activity
IL137351A0 (en) 1998-02-12 2001-07-24 Univ Rutgers Heterocyclic topoisomerase poisons
US7141603B2 (en) * 1999-02-19 2006-11-28 The Regents Of The University California Antitumor agents
US6025328A (en) 1998-02-20 2000-02-15 The Regents Of The University Of California Antitumor agents
US6117878A (en) * 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
US6355678B1 (en) * 1998-06-29 2002-03-12 Parker Hughes Institute Inhibitors of the EGF-receptor tyrosine kinase and methods for their use
US6800649B1 (en) * 1998-06-30 2004-10-05 Parker Hughes Institute Method for inhibiting c-jun expression using JAK-3 inhibitors
US6323190B1 (en) 1998-07-31 2001-11-27 The Univeristy Of Georgia Research Foundation, Inc. Estrogen mimetics lacking reproductive tract effects
US7378400B2 (en) * 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
US7214665B2 (en) * 2001-10-01 2007-05-08 University Of Virginia Patent Foundation 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US7427606B2 (en) * 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US6166003A (en) * 1999-02-17 2000-12-26 Lkt Laboratories, Inc. Heterocyclic compounds for cancer chemoprevention
WO2000048622A2 (en) 1999-02-22 2000-08-24 University Of Iowa Research Foundation Method for inhibiting inflammatory responses
US6080747A (en) 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
WO2000053610A2 (en) 1999-03-09 2000-09-14 Pharmacia & Upjohn Company 4-OXO-4,7-DIHYDRO-THIENO[2,3-b]PYRIDINE-5-CARBOXAMIDES AS ANTIVIRAL AGENTS
US7064114B2 (en) * 1999-03-19 2006-06-20 Parker Hughes Institute Gel-microemulsion formulations
US6306897B1 (en) 1999-03-19 2001-10-23 Parker Hughes Institute Calanolides for inhibiting BTK
US6258820B1 (en) * 1999-03-19 2001-07-10 Parker Hughes Institute Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines
US6407091B1 (en) * 1999-04-15 2002-06-18 Research Corporation Technologies, Inc. β-lactamase inhibiting compounds
US6930101B1 (en) 1999-05-17 2005-08-16 The Regents Of The University Of California Thiazolopyrimidines useful as TNFα inhibitors
US6322771B1 (en) 1999-06-18 2001-11-27 University Of Virginia Patent Foundation Induction of pharmacological stress with adenosine receptor agonists
WO2000078793A2 (en) 1999-06-22 2000-12-28 University Of Louisville Research Foundation, Inc. Antimicrobial agents
US6946458B2 (en) 1999-07-22 2005-09-20 University Of South Florida N-thiolated beta-lactams: novel antibacterial agents for methicillin-resistant Staphylococcus aureus
US7151100B1 (en) * 1999-07-23 2006-12-19 The Regents Of The University Of California Indole compounds useful for the treatment of cancer
US6852685B1 (en) 1999-08-17 2005-02-08 Board Of Regents, The University Of Texas System Use of colostrinin, constituent peptides thereof, and analogs thereof to promote neuronal cell differentiation
US7119064B2 (en) * 1999-08-17 2006-10-10 Board Of Regents, The University Of Texas System Use of colostrinin, constituent peptides thereof, and analogs thereof as modulators of intracellular signaling molecules
US6903068B1 (en) 1999-08-17 2005-06-07 Board Of Regents, The University Of Texas System Use of colostrinin, constituent peptides thereof, and analogs thereof for inducing cytokines
WO2001012650A2 (en) * 1999-08-17 2001-02-22 The University Of Texas System Use of colostrinin, constituent peptides thereof, and analogs thereof as oxidative stress regulators
MY125942A (en) 1999-09-07 2006-09-29 Upjohn Co Aminoalkoxy carbazoles for the treatment of cns diseases
US7026469B2 (en) * 2000-10-19 2006-04-11 Wake Forest University School Of Medicine Compositions and methods of double-targeting virus infections and cancer cells
US6670341B1 (en) 1999-10-28 2003-12-30 Wake Forest University Health Sciences Compositions and methods for double-targeting virus infections and targeting cancer cells
US6740650B2 (en) 1999-10-29 2004-05-25 Rutgers, The State University Of New Jersey Heterocyclic cytotoxic agents
AU1608801A (en) 1999-11-15 2001-05-30 Parker Hughes Institute Diamino platinum (ii) antitumor complexes
US6649654B1 (en) * 1999-11-23 2003-11-18 The Regents Of The University Of California Methods for identifying and using IKK inhibitors
US6589992B2 (en) 1999-11-30 2003-07-08 Parker Hughes Institute Inhibiting collagen-induced platelet aggregation
US6685928B2 (en) 1999-12-07 2004-02-03 Rutgers, The State University Of New Jersey Therapeutic compositions and methods
US20040038948A1 (en) 1999-12-07 2004-02-26 Uhrich Kathryn E. Therapeutic compositions and methods
AU2001231016A1 (en) * 2000-01-20 2001-07-31 Regents Of The University Of Minnesota Peptides with antibacterial activity
WO2001070742A1 (en) 2000-03-21 2001-09-27 Pharmacia & Upjohn Company 4-hydroxy-1,8-naphthyridine-3-carboxamides as antiviral agents
BR0109391A (pt) 2000-03-21 2003-06-03 Upjohn Co 4-hidroxicinolina-3-carboxiamidas como agentes antivirais
MXPA02009249A (es) 2000-03-21 2003-03-12 Upjohn Co 4-oxo-1,4-dihidro(1,8)naftiridin-3-carboxamidas como agentes antivirales.
US6682892B2 (en) 2000-07-13 2004-01-27 Pharmacia & Upjohn Company Method for treating herpes viruses
US20040152672A1 (en) * 2000-08-09 2004-08-05 Carson Dennis A. Indole compounds useful for the treatment of cancer
US6696441B1 (en) 2000-08-11 2004-02-24 The Regents Of The University Of California Inhibition of p53-induced stress response
US6951847B2 (en) * 2000-09-29 2005-10-04 Regents Of The University Of Minnesota Methods of treating fungal infections using lupeol
AU2001294953A1 (en) 2000-09-29 2002-04-08 Regents Of The University Of Minnesota Triterpenes having fungicidal activity against yeast
AU2001294959A1 (en) 2000-09-29 2002-04-08 Robert M. Carlson Triterpenes having antibacterial activity
US7309696B2 (en) 2000-10-19 2007-12-18 Wake Forest University Compositions and methods for targeting cancer cells
US6642221B1 (en) 2000-11-15 2003-11-04 Parker Hughes Institute Vanadium compounds as anti-proliferative agents
US6958359B1 (en) * 2000-11-15 2005-10-25 Parker Hughes Institute Vanadium compounds as anti-angiogenic agents
US6878388B1 (en) 2000-11-15 2005-04-12 Parker Hughes Institute Vanadium compounds for treating proliferative cell disorders
US6630462B2 (en) 2000-11-17 2003-10-07 Adolor Corporation Delta agonist analgesics
US20040034045A1 (en) * 2000-11-29 2004-02-19 Parker Hughes Institute Inhibitors of thrombin induced platelet aggregation
WO2002060936A2 (en) * 2001-01-31 2002-08-08 University Of Iowa Research Foundation Vaccine and compositions for the prevention and treatment of neisserial infections
US7261901B2 (en) * 2001-01-31 2007-08-28 University Of Iowa Research Foundation Vaccine and compositions for the prevention and treatment of neisserial infections
US6703524B2 (en) * 2001-02-20 2004-03-09 Lkt Laboratories, Inc. Organoselenium compounds for cancer chemoprevention
US7232829B2 (en) * 2001-04-06 2007-06-19 Regents Of The University Of Minnesota Therapeutic compounds and methods
GB0111872D0 (en) * 2001-05-15 2001-07-04 Northwick Park Inst For Medica Therapeutic agents and methods
US6960738B2 (en) * 2001-05-29 2005-11-01 Koninklijke Philips Electronics N.V. Metal-ceramic bond
US7601846B2 (en) * 2001-06-26 2009-10-13 The Regents Of The University Of California Compounds having activity as inhibitors of apoptosis
US20030232794A1 (en) * 2001-06-26 2003-12-18 Cottam Howard B. Use of STAT-6 inhibitors as therapeutic agents
CA2454413A1 (en) * 2001-07-24 2003-03-13 Alamx, L.L.C. 7-alkylidene-3-substituted-3-cephem-4-carboxylates as beta-lactamase inhibitors
US6753414B2 (en) * 2001-08-07 2004-06-22 University Of Iowa Research Foundation, Inc. Process for preparing saponin compounds
ATE306486T1 (de) 2001-08-08 2005-10-15 Pharmacia & Upjohn Co Llc Therapeutische 1h-pyrido(4,3-b)indole
US20030171377A1 (en) * 2001-08-29 2003-09-11 Bigge Christopher Franklin Antidiabetic agents
WO2003020728A1 (en) 2001-08-30 2003-03-13 Pharmacia & Upjohn Company 4-THIOXO-4,7-DIHYDRO-THIENO[2,3-b]PYRIDINE-5-CARBOTHIOAMIDES AS ANTIVIRAL AGENTS
JP4714413B2 (ja) * 2001-08-31 2011-06-29 トムソン ライセンシング オーディオビジュアルストリームのためのシーケンスカウンタ
AU2002336749A1 (en) * 2001-09-21 2003-04-01 Pharmacia And Upjohn Company Tricyclic indole derivatives as 5-ht ligands
EP1430017A2 (en) 2001-09-26 2004-06-23 Theravance, Inc. Substituted phenol compounds useful for anesthesia and sedation
AU2002334969A1 (en) * 2001-10-09 2003-04-22 Sylvie Barchechath Use of stat-6 inhibitors as therapeutic agents
DE60238435D1 (de) * 2001-10-26 2011-01-05 Scripps Research Inst Gezielte thrombose durch gewebefaktor polypeptiden
EP1453812B1 (en) 2001-11-14 2008-08-20 Rutgers, The State University Cytotoxic agents
SI1465625T1 (sl) 2001-11-14 2010-06-30 Univ Rutgers Solubilizirani topoizomerazni strupi
AU2002357762A1 (en) 2001-11-23 2003-06-10 Theodore James Anastasion Improved synthesis of polyanhyrides
US7030141B2 (en) * 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
WO2003063779A2 (en) * 2002-01-25 2003-08-07 Regents Of The University Of Minnesota Selective analgesic agents
US7968605B2 (en) * 2002-02-04 2011-06-28 ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda. Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
US20080026984A1 (en) * 2002-02-04 2008-01-31 Alfama - Investigacao E Desenvolvimento De Productos Farmaceuticos Lda Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
WO2003066067A2 (en) * 2002-02-04 2003-08-14 Alfama - Investigaçao E Desenvolvimento De Produtos Farmaceuticos Lda. Use of co-releasing compounds for the manufacture of a medicament for the treatment of inflammatory diseases
KR20040108651A (ko) 2002-02-07 2004-12-24 루트거스, 더 스테이트 유니버시티 오브 뉴 저지 치료용 폴리에스테르 및 폴리아미드
WO2003072053A2 (en) 2002-02-22 2003-09-04 The Curators Of The University Of Missouri Compounds for treatment of copper overload
US20050032713A1 (en) * 2002-03-27 2005-02-10 Wurtman Richard J. Platelet-activating factor antagonists as analgesic, anti-inflammatory, uterine contraction inhibiting, and anti-tumor agents
AU2003224874A1 (en) * 2002-04-04 2003-10-27 Alamx, L.L.C. INHIBITORS OF SERINE AND METALLO-ss-LACTAMASES
MXPA04010560A (es) * 2002-04-25 2005-08-15 Scripps Research Inst Tratamiento y prevencion de condiciones pulmonares.
US7026472B2 (en) * 2002-05-06 2006-04-11 University Of South Florida Methods for preventing and treating cancer using N-thiolated β-lactam compounds and analogs thereof
US20040156799A1 (en) * 2002-06-04 2004-08-12 Zigang Dong Cancer treatment method and compositions
UA79293C2 (en) * 2002-07-03 2007-06-11 Univ Wayne State 4-(7'-halo-2-quino (xa-) linyloxy)phenoxy propionic acid derivatives as antineoplastic agents
US20060093595A1 (en) * 2002-07-05 2006-05-04 Mahesh Jayachandra Methods, compositions and kits for treating damage to excitable tissue
WO2004014918A1 (en) * 2002-08-09 2004-02-19 Rutgers, The State University Nitro and amino substituted topoisomerase agents
JP2005538175A (ja) * 2002-09-11 2005-12-15 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー 血液凝固過程に関与する第Ｘａ因子および他セリンプロテアーゼのインヒビター
WO2004026116A2 (en) * 2002-09-19 2004-04-01 The Regents Of The University Of California Use of etodoclac to treat hyperplasia
EP2447278B1 (en) 2002-10-10 2015-04-08 Cornell Research Foundation, Inc. Novel immunogenic proteins of Leptospira
US20060183106A1 (en) * 2002-10-18 2006-08-17 Adam Siddiqui-Jain Processes for identifying quadruplex-targeted antiviral molecules
US20050042300A1 (en) * 2002-10-22 2005-02-24 Istvan Boldogh Use of colostrinin, constituent peptides thereof, and analogs thereof as inhibitors of apoptosis and other cellular damage
WO2004039362A2 (en) * 2002-10-28 2004-05-13 Paraquest, Inc. Hypoestoxides, derivatives and agonists thereof for use in the treatment and prophylaxis of hyperlipidemia
JP2006520584A (ja) 2002-11-08 2006-09-14 アブリンクス エン．ヴェー． 安定化単一ドメイン抗体
EP1558645B1 (en) 2002-11-08 2011-07-27 Ablynx N.V. Stabilized single domain antibodies in pharmaceutical composition adapted for inhalation
GB2395432B (en) * 2002-11-20 2005-09-14 Northwick Park Inst For Medica Therapeutic delivery of carbon monoxide to extracorporeal and isolated organs
EP1599183A2 (en) * 2002-11-26 2005-11-30 Gilead Sciences, Inc. Method of drug loading in liposomes by gradient
AU2003296944A1 (en) * 2002-12-10 2004-06-30 George Koob A method for treatment of drug addiction and for screening of pharmaceutical agents therefor
US8119854B2 (en) * 2002-12-10 2012-02-21 Pietro P. Sanna Role of proteoglycans in drug dependence
WO2004062583A2 (en) * 2003-01-07 2004-07-29 University Of Iowa Research Foundation Vaccine and method for preventing biofilm formation
JP2006517789A (ja) 2003-01-10 2006-08-03 アブリンクス エン．ヴェー． 治療用ポリペプチド、その相同物、その断片、および血小板媒介凝集の調節での使用
US20050079512A1 (en) * 2003-02-26 2005-04-14 Emerson Beverly M. Methods of modulating gene expression
CA2520732C (en) 2003-03-28 2012-12-04 Sloan-Kettering Institute For Cancer Research Migrastatin analogs and uses thereof
WO2004091627A2 (en) * 2003-04-07 2004-10-28 Cylene Pharmaceuticals, Inc. Heterocyclic substituted 1,4-dihydro-4-oxo-1,8-naphthpyridine analogs
WO2004091504A2 (en) 2003-04-07 2004-10-28 Cylene Pharmaceuticals, Inc. Substituted quinobenzoxazine analogs
US7354916B2 (en) * 2003-04-07 2008-04-08 Cylene Pharmaceuticals Substituted quinobenzoxazine analogs
US7507727B2 (en) * 2003-04-07 2009-03-24 Cylene Pharmaceuticals, Inc. Substituted quinobenzoxazine analogs and methods of using thereof
US20040248880A1 (en) * 2003-04-25 2004-12-09 Jacobsen Eric Jon 1,2,3,4,5,6-Hexahydroazepino[4,5-B]indoles containing arylsulfones at the 9-position
EP1635858A4 (en) * 2003-05-29 2009-08-26 Scripps Research Inst TARGETED RELEASE ON CELLS EXPRESSING LEGUMINUM
DE602004028880D1 (de) 2003-06-25 2010-10-07 Burnham Inst La Jolla Analoga von Apogossypol zur Verwendung in der Behandlung von Krebs
WO2005003140A1 (en) * 2003-07-02 2005-01-13 Pharmacia & Upjohn Company Llc 4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamides as antiviral agents
CN1894250B (zh) 2003-08-25 2010-06-09 PGx健康有限责任公司 取代的8-杂芳基黄嘌呤
EP2520654B8 (en) 2003-08-26 2017-04-19 The Regents of the University of Colorado, a body corporate Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections
US9532994B2 (en) 2003-08-29 2017-01-03 The Regents Of The University Of California Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins
AU2004285122A1 (en) * 2003-10-17 2005-05-12 Regents Of The University Of Minnesota Modified polypeptides with therapeutic activity and methods of use
DE60334645D1 (de) 2003-11-07 2010-12-02 Ablynx Nv Camelidae schwere ketten antikörper vhhs gegen epidermalen wachstumfaktor rezeptor (egfr) und ihre verwendung
WO2005055994A1 (en) * 2003-12-04 2005-06-23 The Scripps Research Institute Treatment and preventions of asthma
CA2550447A1 (en) * 2003-12-19 2005-07-07 The Regents Of The University Of California Methods and materials for assessing prostate cancer therapies
NZ589967A (en) 2004-01-14 2012-07-27 Gilead Sciences Inc Lipid-based dispersions useful for drug delivery
WO2005072766A2 (en) * 2004-01-27 2005-08-11 Boys Town National Research Hospital Peptides that bind to hsp90 proteins
US8841326B2 (en) 2004-02-12 2014-09-23 Stc.Unm Therapeutic curcumin derivatives
US20050187191A1 (en) * 2004-02-20 2005-08-25 Kucera Louis S. Methods and compositions for the treatment of respiratory syncytial virus
US20050187192A1 (en) * 2004-02-20 2005-08-25 Kucera Pharmaceutical Company Phospholipids for the treatment of infection by togaviruses, herpes viruses and coronaviruses
NZ550102A (en) * 2004-02-24 2010-10-29 Univ California Methods and materials for assessing prostate cancer therapies and compounds (thiohydantoine derivatives)
LT2574341T (lt) 2004-03-29 2017-09-11 University Of South Florida Navikų ir vėžio efektyvus gydymas triciribino fosfatu
WO2006001967A2 (en) * 2004-05-25 2006-01-05 Sloan-Kettering Institute For Cancer Research Migrastatin analogs in the treatment of cancer
NZ553288A (en) 2004-08-02 2010-12-24 Univ Virginia 2-propynyl adenosine analogs with modified 5'-ribose groups having A2A agonist activity
WO2006023272A1 (en) * 2004-08-02 2006-03-02 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having a2a agonist activity
WO2006028618A1 (en) * 2004-08-02 2006-03-16 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
EP1793832B1 (en) * 2004-08-25 2014-07-23 University of Iowa Research Geranylgeranyl pyrophosphate synthase inhibitors
US20080213345A1 (en) * 2004-09-13 2008-09-04 Gilead Sciences, Inc. Delivering Iron to an Animal
WO2006034478A2 (en) * 2004-09-23 2006-03-30 Sloan-Kettering Institute For Cancer Research Isomigrastatin analogs in the treatment of cancer
US7718680B2 (en) * 2004-09-23 2010-05-18 Burnham Institute For Medical Research Inhibition of lethal factor protease activity from anthrax toxin
JP5113523B2 (ja) * 2004-10-13 2013-01-09 アブリンクス ナームローゼ フェンノートシャップ アミロイド−βに対するナノ抗体及びアルツハイマー病のような神経変性疾患の治療のためのナノ抗体ＴＭを含むポリペプチド
US8697674B2 (en) 2004-12-29 2014-04-15 Naturon, Inc. Xanthurenic acid derivative pharmaceutical compositions and methods related thereto
US7605241B2 (en) * 2005-01-10 2009-10-20 University Of Virginia Patent Foundation Synthesis of inhibitors of p90Rsk
US7691364B2 (en) * 2005-01-28 2010-04-06 Bezwada Biomedical, Llc Functionalized drugs and polymers derived therefrom
ATE541571T1 (de) 2005-05-13 2012-02-15 Univ California Diarylhydantoin-verbindung
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
DK2949668T3 (da) 2005-05-18 2019-11-11 Ablynx Nv Forbedrede nanobodies tm mod tumornekrosefaktor-alfa
EP2444424B1 (en) 2005-05-20 2018-08-08 Ablynx N.V. Improved nanobodies tm for the treatment of aggregation-mediated disorders
US20070025910A1 (en) 2005-07-29 2007-02-01 Norenberg Jeffrey P Anticancer therapy
WO2007019308A2 (en) * 2005-08-03 2007-02-15 The Regents Of The University Of California Illudin analogs useful as anticancer agents
CN101304748A (zh) 2005-08-22 2008-11-12 加利福尼亚大学董事会 Tlr激动剂
JP5259408B2 (ja) * 2005-08-29 2013-08-07 ユニバーシティ オブ バージニア パテント ファンデーション リソフィリン類縁体とその使用方法
US8871764B2 (en) 2005-08-29 2014-10-28 University Of Virginia Patent Foundation Lisofylline analogs and methods for use
US8318973B2 (en) 2005-10-21 2012-11-27 Bezwada Biomedical, Llc Functionalized sinapic acid and methyl sinapate
WO2007056113A2 (en) * 2005-11-02 2007-05-18 Cylene Pharmaceuticals, Inc. Methods for targeting quadruplex sequences
EP1976861A2 (en) * 2005-11-29 2008-10-08 The Scripps Research Institute Inhibiting tumour cell invasion, metastasis and angiogenesis through targetting legumain
US8007526B2 (en) 2005-12-01 2011-08-30 Bezwada Biomedical, Llc Difunctionalized aromatic compounds and polymers therefrom
WO2007078615A2 (en) * 2005-12-15 2007-07-12 Cavit Sciences, Inc Methods and compositions for treatment of cancer
WO2007073226A1 (en) * 2005-12-20 2007-06-28 Alfama - Investigação E Desenvolvimento De Produtos Farmacêuticos Lda Method for treating a mammal by administration of a compound having the ability to release co
US20070244057A1 (en) * 2006-01-20 2007-10-18 Henry Paulson Suppressing polyglutamine aggregation and toxicity
GB0601394D0 (en) 2006-01-24 2006-03-01 Hemocorm Ltd Therapeutic delivery of carbon monoxide
US7615649B2 (en) 2006-01-26 2009-11-10 Iowa State University Research Foundation, Inc, Synthesis of polycyclic procyanidins
US8178509B2 (en) * 2006-02-10 2012-05-15 University Of Virginia Patent Foundation Method to treat sickle cell disease
JP5256049B2 (ja) * 2006-02-21 2013-08-07 ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション 抗癌剤
EP1993558B1 (en) 2006-02-27 2014-07-30 The Regents of The University of California Oxysterol compounds and the hedgehog pathway
TWI403321B (zh) 2006-02-28 2013-08-01 Helicon Therapeutics Inc 治療性化合物
EP2007383A4 (en) * 2006-03-22 2010-09-15 Univ California INHIBITORS OF PROTEIN PRENYLTRANSFERASES
PT2656841T (pt) 2006-03-27 2016-09-28 Univ California Modulador do recetor de androgénios para o tratamento de cancro da próstata e doenças associadas ao recetor de androgénios
KR101600230B1 (ko) 2006-03-29 2016-03-04 더 리전트 오브 더 유니버시티 오브 캘리포니아 디아릴티오히단토인 화합물
US8093235B2 (en) 2006-04-25 2012-01-10 Rutgers, The State University Of New Jersey Macrocyclic compounds which stabilize G-Quadruplex DNA and RNA
WO2007139778A2 (en) * 2006-05-22 2007-12-06 University Of Virginia Patent Foundation Rhamnose substituents of sl0101 and therapeutic uses thereof
CA2653941C (en) 2006-05-31 2013-01-08 The Regents Of The University Of California Substituted amino purine derivatives and uses thereof
EP2046315B1 (en) * 2006-06-02 2013-04-10 The Ohio State University Research Foundation Therapeutic agents for the treatment of mantle cell lymphoma
US20110112086A1 (en) * 2006-06-08 2011-05-12 Cylene Pharmaceuticals, Inc. Pyridinone analogs
WO2007146831A2 (en) * 2006-06-08 2007-12-21 Cylene Pharmaceuticals, Inc. Quinolone analogs derivatized with sulfonic acid, sulfonate or sulfonamide
UA105164C2 (en) 2006-06-16 2014-04-25 Догвуд Фармасьютикалз, Инк Substituted 8-[6-amino-3-pyridyl]xanthines
US8188063B2 (en) * 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
EP2102144A4 (en) 2006-09-13 2011-03-23 Univ Rutgers ACTIVE SUBSTANCES AND THEIR OLIGOMERS AND POLYMERS
US20080206287A1 (en) * 2006-09-18 2008-08-28 Reed John C Use of cyclosporin A to sensitize resistant cancer cells to death receptor ligands
WO2008108825A2 (en) * 2006-10-10 2008-09-12 Burnham Institute For Medical Research Neuroprotective compositions and methods
US8034829B2 (en) 2006-11-17 2011-10-11 Rexahn Pharmaceuticals, Inc. 5, 6, or 7-substituted-3-(hetero)arylisoquinolinamine derivatives and therapeutic use thereof
JP2010511034A (ja) * 2006-11-29 2010-04-08 ファイザー・プロダクツ・インク 第Ｘａ因子阻害剤としての（Ｒ）−５−メチル−４，５−ジヒドロ−ピラゾール−１，５−ジカルボン酸１−［（４−クロロ−フェニル）−アミド］５−｛［２−フルオロ−４−（２−オキソ−２Ｈ−ピリジン−１−イル）−フェニル］−アミド｝
WO2008074840A2 (en) 2006-12-19 2008-06-26 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders
AU2007336242B2 (en) 2006-12-19 2012-08-30 Ablynx N.V. Amino acid sequences directed against GPCRs and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
EP2111385B1 (en) 2007-02-06 2014-11-12 University Of Louisville Research Foundation, Inc. Substituted alkine derivatives as anti-cancer agents
BRPI0807196A2 (pt) 2007-02-07 2014-06-03 Univ California Método para prevenir ou inibir uma infecção bacteriana, vacina, composto, e, método para prevenir, tratar ou inibir a asma
US20100143270A1 (en) * 2007-02-21 2010-06-10 University Of Louisville Research Foubdation Therapeutic cotinine compositions
JP2010520236A (ja) 2007-02-28 2010-06-10 ユニバーシティ オブ バージニア パテント ファンデーション リソフィリンアナログとその使用法
US8569449B2 (en) 2007-05-08 2013-10-29 University Of Louisville Research Foundation, Inc. Synthetic peptides and peptide mimetics
MX2010000474A (es) 2007-07-12 2010-06-23 Univ South Florida Inhibidores de proteina serina/treonina quinasa a/proteina quinasa b con actividad antitumoral.
EP2185568A4 (en) 2007-08-02 2010-08-11 Trustees Rutgers The State Uni THERAPEUTIC COMPOUNDS
WO2009025797A1 (en) * 2007-08-16 2009-02-26 Burnham Institute For Medical Research Compositions and methods for treating symptoms of aging
AU2008293542B9 (en) 2007-08-27 2014-08-07 Dart Neuroscience (Cayman) Ltd. Therapeutic isoxazole compounds
US8217134B2 (en) 2007-08-30 2012-07-10 Bezwada Biomedical, Llc Controlled release of biologically active compounds
US8048980B2 (en) * 2007-09-17 2011-11-01 Bezwada Biomedical, Llc Hydrolysable linkers and cross-linkers for absorbable polymers
JP5824213B2 (ja) 2007-10-05 2015-11-25 センワ バイオサイエンシズ インコーポレイテッド キノロン類似体およびそれに関連する方法
CA2703724C (en) * 2007-10-19 2017-07-11 Burnham Institute Of Medical Research Naphthalene-based inhibitors of anti-apoptotic proteins
WO2009055677A1 (en) * 2007-10-24 2009-04-30 University Of South Florida Antibacterial s-heterosubstituted disulfides
EP2220050A2 (en) 2007-10-26 2010-08-25 The Regents Of The University Of California Diarylhydantoin compounds as androgen receptor modulators
WO2009059030A1 (en) * 2007-10-31 2009-05-07 Burnham Institute For Medical Research Pyrazole derivatives as kinase inhibitors
CA2707663C (en) 2007-12-03 2017-05-30 The Regents Of The University Of California Oxysterols for activation of hedgehog signaling, osteoinduction, antiadipogenesis, and wnt signaling
US8058259B2 (en) * 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
EA201001264A1 (ru) * 2008-02-07 2011-04-29 Дзе Регентс Оф Дзе Юниверсити Оф Калифорния Способ лечения заболеваний мочевого пузыря с помощью активатора tlr7
US8142764B2 (en) 2008-02-27 2012-03-27 University Of Louisville Research Foundation Synthetic biofilm-inhibiting peptides
US20090247466A1 (en) * 2008-03-10 2009-10-01 University Of Louisville Research Foundation Neuroprotective integrin-binding peptide and angiopoietin-1 treatments
US20110046101A1 (en) * 2008-03-17 2011-02-24 Dmitrienko Gary I Bate-lactamase inhibitors
WO2009146112A1 (en) * 2008-04-02 2009-12-03 University Of Virginia Patent Foundation Compositions and methods for inhibiting sphingosine kinase
CA2720763A1 (en) 2008-04-07 2009-10-15 Ablynx Nv Amino acid sequences directed against the notch pathways and uses thereof
CN102099378B (zh) 2008-05-16 2016-01-20 埃博灵克斯股份有限公司 针对CXCR4和其他GPCRs的氨基酸序列以及包含所述氨基酸序列的多肽
US9872867B2 (en) * 2008-06-06 2018-01-23 Tanya Kuritz Methods and compositions for modulation of innate immunity
US8716334B2 (en) 2008-06-17 2014-05-06 Ben Gurion University Of The Negev Research And Development Authority Substituted cyclohexylidene-ethylidene-octahydro-indene compounds
US8673910B2 (en) * 2008-06-30 2014-03-18 H. Lee Moffitt Cancer Center And Research Institute Proteasome inhibitors for selectively inducing apoptosis in cancer cells
US7947717B2 (en) * 2008-07-18 2011-05-24 Burnham Institute For Medical Research Inhibitors of lethal factor protease
US9125821B2 (en) 2008-07-28 2015-09-08 The Regents Of The University Of California Nanodrug targeting protein geranylgeranylation
US20110178138A1 (en) * 2008-07-28 2011-07-21 The Regents Of The University Of California Inhibitors of protein prenyltransferases
US20110142795A1 (en) 2008-08-05 2011-06-16 University Of South Florida Methods of treating cognitive impairment
US9132168B2 (en) 2008-08-05 2015-09-15 University Of South Florida Methods of treating cognitive impairment
US8871983B2 (en) * 2008-08-08 2014-10-28 University Of Florida Research Foundation, Inc. Lipid compounds for suppression of tumorigenesis
US9801865B2 (en) 2008-09-24 2017-10-31 The United States Of America As Represented By The Department Of Veteran Affairs Materials and methods for diagnosis, prevention and/or treatment of stress disorders and conditions associated with abeta peptide aggregation
US8124654B2 (en) * 2008-11-11 2012-02-28 Immune Modulation, Inc. Derivatives of hypoestoxide and related compounds
TW201038578A (en) 2009-01-30 2010-11-01 Univ Rutgers Methods to treat cancer
WO2010088924A1 (en) 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
MX2011008500A (es) * 2009-02-11 2011-09-26 Univ California Moduladores del receptor tipo toll y tratamiento de enfermedades.
JP5773888B2 (ja) 2009-03-06 2015-09-02 ラットガーズ，ザ・ステート・ユニバーシティ・オブ・ニュージャージー 癌治療に用いられるメチレンジオキシベンゾ［ｉ］フェナントリジン誘導体
JP2012521365A (ja) 2009-03-20 2012-09-13 ユニバーシティー オブ アイオワ リサーチ ファウンデーション 抗結核剤としてのプレニル化ビスホスホネート
AU2010233658B2 (en) 2009-04-10 2013-11-28 Ablynx Nv Improved amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of IL-6R related diseases and disorders
US8487131B2 (en) 2009-04-15 2013-07-16 Sanford-Burnham Medical Research Institute Optically pure apogossypol derivative as pan-active inhibitor of anti-apoptotic B-cell lymphoma/leukemia-2 (BCL-2)
JP2012524101A (ja) 2009-04-15 2012-10-11 サンフォード−バーンハム メディカル リサーチ インスティテュート 抗アポトーシスタンパク質のナフタレンベースのインヒビター
US20120108823A1 (en) 2009-04-22 2012-05-03 The Ohio State University Research Foundation Anti-francisella agents
WO2010132504A1 (en) 2009-05-11 2010-11-18 University Of Tennessee Research Foundation Anti-inflammatory quinic acid derivatives for radioprotection/radiomitigation
WO2010132684A2 (en) 2009-05-13 2010-11-18 University Of Virginia Patent Foundation Inhibitors of inv(16) leukemia
MX2012000113A (es) 2009-06-30 2012-02-29 Forest Lab Holdings Ltd Compuestos alcoxi-carbonil-amino-alquinil-adenosina y derivados de los mismos como agonistas a2ar.
WO2011005871A1 (en) 2009-07-07 2011-01-13 Pgxhealth, Llc Substituted 8-[6-carbonylamine-3-pyridyl]xanthines as adenosine a2b antagonists
SG177557A1 (en) 2009-07-09 2012-02-28 Cbt Dev Ltd Combined preparation for use as a medicament
BR112012002110A2 (pt) 2009-07-31 2018-04-10 Biocryst Pharm Inc derivados de pirrolo[1,2-b]piridazina como inibidores de janus cinase
US9040673B2 (en) 2009-08-14 2015-05-26 University Of Virginia Patent Foundation Synthesis and identification of novel RSK-specific inhibitors
TW201111385A (en) 2009-08-27 2011-04-01 Biocryst Pharm Inc Heterocyclic compounds as janus kinase inhibitors
US8642088B2 (en) 2009-09-04 2014-02-04 Wisconsin Alumni Research Foundation Tannin-chitosan composites
WO2011028638A1 (en) 2009-09-04 2011-03-10 Schering Corporation Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors
MX2012004064A (es) * 2009-10-08 2012-06-08 Sanford Burnham Med Res Inst Derivados apogosipolona como agentes antineoplasicos.
US8796300B2 (en) 2009-11-05 2014-08-05 Rutgers, The State University Of New Jersey Therapeutic compounds
WO2011069075A2 (en) 2009-12-04 2011-06-09 Grant Jon E Treating impulse control disorders with catechol-o- methyl-transferase inhibitors
AU2010336437A1 (en) 2009-12-23 2012-07-19 Biocryst Pharmaceuticals, Inc. Heterocyclic compounds as Janus kinase inhibitors
EP2516396A1 (en) 2009-12-23 2012-10-31 Wayne State University Therapeutic compounds
ES2668380T3 (es) 2010-02-16 2018-05-17 Aragon Pharmaceuticals, Inc. Moduladores de receptores de andrógenos y sus usos
EP2539348A4 (en) 2010-02-26 2013-07-24 Gary Igor Dmitrienko CEPHALOSPORIN DERIVATIVES AS BETA LACTAMASE HEMMER AND COMPOSITIONS THEREFOR AND METHOD FOR THEIR USE
JP2013523748A (ja) 2010-03-29 2013-06-17 サーモディクス，インコーポレイテッド 注射用薬物送達製剤
CN103108861A (zh) 2010-04-02 2013-05-15 Tsrl公司 神经氨酸酶抑制剂
WO2011127344A2 (en) 2010-04-08 2011-10-13 University Of Virginia Patent Foundation Method to detect and treat infectious or inflammatory diarrhea
WO2011130740A2 (en) 2010-04-16 2011-10-20 H. Lee Moffitt Cancer Center And Research Institute, Inc. Pyridylthiazole-based ureas as inhibitors of rho associated protein kinase (rock) and methods of use
WO2011133696A2 (en) 2010-04-20 2011-10-27 Regents Of The University Of Minnesota Methods of suppressing atherosclerosis
KR20130083389A (ko) 2010-05-28 2013-07-22 바이오크리스트파마슈티컬즈,인코포레이티드 야누스 키나아제 억제제로서 헤테로사이클릭 화합물
CA2810162A1 (en) 2010-06-09 2011-12-15 Rutgers, The State University Of New Jersey Antimicrobial agents
US9102617B2 (en) 2010-06-25 2015-08-11 Rutgers, The State University Of New Jersey Antimicrobial agents
US8741317B2 (en) 2010-08-19 2014-06-03 Rutgers, The State University Of New Jersey Slow-degrading polymers comprising salicylic acid for undelayed and sustained drug delivery
WO2012027494A1 (en) 2010-08-24 2012-03-01 Regents Of The University Of Minnesota Bispecific targeting reagents
US20120083473A1 (en) 2010-09-21 2012-04-05 Johanna Holldack Treatment of conditions by toll-like receptor modulators
WO2012061120A1 (en) 2010-10-25 2012-05-10 Regents Of The University Of Minnesota Therapeutic composition for treatment of glioblastoma
US20130216553A1 (en) 2010-10-29 2013-08-22 University Of Connecticut Compositions and Methods for Modulation and Detection of Immune and Inflammatory Responses
EP2635274B1 (en) 2010-11-01 2017-12-06 The Ohio State University Research Foundation Anti-staphylococcal celecoxib derivatives
EP2646553A4 (en) 2010-11-12 2015-01-07 Santaris Pharma As COMPOSITIONS AND METHODS OF TREATING ANDROGEN RECEPTOR DEPENDENT DISORDERS INCLUDING CANCER
US8309768B2 (en) 2010-11-29 2012-11-13 The Ohio State University Research Foundation FTY720-derived anticancer agents
WO2012087889A2 (en) 2010-12-20 2012-06-28 The Ohio State University Research Foundation Dna methylation inhibitors
US11279674B2 (en) 2011-01-03 2022-03-22 The William M. Yarbrough Foundation Isothiocyanate functional surfactant and associated method of use
US10640464B2 (en) 2011-01-03 2020-05-05 The William M. Yarbrough Foundation Use of isothiocyanate functional surfactants as Nrf2 inducers to treat epidermolysis bullosa simplex and related diseases
US10647668B2 (en) 2011-01-03 2020-05-12 The William M. Yarbrough Foundation Isothiocyanate functional surfactant and associated method of use
US9962361B2 (en) 2011-01-03 2018-05-08 The William M. Yarbrough Foundation Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use
US10308599B2 (en) 2011-01-03 2019-06-04 The William M. Yarbrough Foundation Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use
US11407713B2 (en) 2011-01-03 2022-08-09 The William M. Yarbrough Foundation Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use
US10273205B2 (en) 2011-01-03 2019-04-30 The William M. Yarbrough Foundation Isothiocyanate functional surfactants, formulations incorporating isothiocyanate functional surfactants and associated methods for treating biofilms
US8933119B2 (en) 2011-01-03 2015-01-13 The William M. Yarbrough Foundation Method for treating phytophotodermatitis
US8865765B2 (en) 2011-01-12 2014-10-21 The William M. Yarbrough Foundation Method for treating eczema
CN106278999B (zh) 2011-02-07 2019-10-25 比奥根Ma公司 S1p调节剂
US9532969B2 (en) 2011-02-08 2017-01-03 The William M. Yarbrough Foundation Method for treating psoriasis
AU2012225574A1 (en) 2011-03-07 2013-09-26 University Of Louisville Research Foundation, Inc. Predictive marker of DNMT1 inhibitor therapeutic efficacy and methods of using the marker
WO2012135697A2 (en) 2011-03-30 2012-10-04 H. Lee Moffitt Cancer Center & Research Institute Inc. Novel rho kinase inhibitors and methods of use
WO2012138774A2 (en) 2011-04-04 2012-10-11 University Of Iowa Research Foundation Methods of improving vaccine immunogenicity
EP2694079B1 (en) 2011-04-06 2018-01-17 Rutgers, The State University of New Jersey Polymers and methods for the treatment of pain
US9163044B2 (en) 2011-04-19 2015-10-20 Alfama, Inc. Carbon monoxide releasing molecules and uses thereof
WO2012145678A1 (en) 2011-04-20 2012-10-26 Regents Of The University Of Minnesota Anti-cancer and anti-inflammatory parthenolide compounds
WO2012177770A1 (en) 2011-06-20 2012-12-27 Rutgers, The State University Of New Jersey Bipartite inhibitors of bacterial rna polymerase
US9133230B2 (en) 2011-06-21 2015-09-15 The United States Of America As Represented By The Department Of Veterans Affairs Hydrazone derivatives having potent antitumor activity toward multi-drug resistant tumor cells
WO2013009647A1 (en) 2011-07-08 2013-01-17 Regents Of The University Of Minnesota Glutathione analogs and uses thereof
JP6134710B2 (ja) 2011-07-21 2017-05-24 アルファーマ インコーポレイテッドＡｌｆａｍａ，Ｉｎｃ． 一酸化ルテニウム放出分子およびその使用
WO2013016206A1 (en) 2011-07-22 2013-01-31 University Of Louisville Research Foundation, Inc. Anti-biofilm compounds
CN103997894B (zh) 2011-07-29 2016-08-24 麦迪韦逊前列腺治疗股份有限公司 乳癌的治疗
US20150017091A1 (en) 2011-08-18 2015-01-15 Cornell University Detection and treatment of metastatic disease
WO2013028866A1 (en) 2011-08-24 2013-02-28 Regents Of The University Of Minnesota Therapeutic compounds and methods
WO2013033345A1 (en) 2011-08-30 2013-03-07 Regents Of The University Of Minnesota Immunomodulators and immunomodulator conjugates
EP2750508A4 (en) 2011-08-30 2015-01-14 Univ Wayne State COMPOUNDS AND THERAPEUTIC METHODS
EP2763658B1 (en) 2011-09-08 2021-06-23 Western University Of Health Sciences Targeted liposomes in cancer therapy
WO2013040227A2 (en) 2011-09-15 2013-03-21 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University Therapeutic compounds
AU2012331702B2 (en) 2011-11-04 2017-10-26 Laurentia Holding B.V. Liposomal corticosteroids for treatment of inflammatory disorders in humans
WO2013101719A2 (en) * 2011-12-27 2013-07-04 Northeast Ohio Medical University Amooranin compounds and analogs thereof and related methods of use
WO2013103969A1 (en) 2012-01-05 2013-07-11 Rutgers, The State University Of New Jersey Antibacterial agents: phloroglucinol derivatives
JP2015504674A (ja) 2012-01-11 2015-02-16 アリゾナ ボード オブ リージェンツ ア ボディ コーポレート オブ ザ ステイト オブ アリゾナ アクティング フォー アンド オン ビハーフ オブ アリゾナ ステイト ユニバーシティーＡｒｉｚｏｎａ Ｂｏａｒｄ Ｏｆ Ｒｅｇｅｎｔｓ， Ａ Ｂｏｄｙ Ｃｏｒｐｏｒａｔｅ Ｏｆ Ｔｈｅ Ｓｔａｔｅ Ｏｆ Ａｒｉｚｏｎａ Ａｃｔｉｎｇ Ｆｏｒ Ａｎｄ Ｏｎ Ｂｅｈａｌｆ Ｏｆ Ａｒｉｚｏｎａ Ｓｔａｔｅ Ｕｎｉｖｅｒｓｉｔｙ 神経疾患タンパク質の二重特異性抗体フラグメントおよび使用方法
US9822108B2 (en) 2012-01-13 2017-11-21 Rutgers, The State University Of New Jersey Antimicrobial agents
EP2804606B1 (en) 2012-01-19 2017-06-28 Hybrid Medical, LLC Topical therapeutic formulations
WO2013109972A2 (en) 2012-01-20 2013-07-25 Regents Of The University Of Minnesota Therapeutic compounds
JP5836402B2 (ja) * 2012-01-25 2015-12-24 Ｓｂｉファーマ株式会社 腫瘍診断剤
US20130195752A1 (en) 2012-02-01 2013-08-01 Regents Of The University Of Minnesota Functionalized nanoparticles and methods of use thereof
CA2863427C (en) 2012-02-01 2022-07-12 The Governors Of The University Of Alberta Use of pdgfr-.alpha. as diagnostic marker for papillary thyroid cancer
WO2013119564A1 (en) 2012-02-06 2013-08-15 Rutgers, The State University Of New Jersey Antibacterial agents: combination of a rifamycin and a switch region inhibitor
WO2013119946A1 (en) 2012-02-08 2013-08-15 Of Virginia Patent Foundation University Long chain base sphingosine kinase inhibitors
EP2819661B1 (en) 2012-03-02 2016-11-09 The Board of Trustees of the University of Illionis Potent anticancer activity via dual compound activation
DK3290035T3 (da) 2012-03-06 2019-08-05 Univ Illinois Procaspase-kombinationsterapi til behandling af cancer
WO2013142712A1 (en) 2012-03-21 2013-09-26 Rutgers, The State University Of New Jersey Antimicrobial agents
US9187446B2 (en) 2012-03-22 2015-11-17 Rutgers, The State University Of New Jersey Antibacterial agents: sidechainfluorinated myxopyronin derivatives
CN104583203B (zh) 2012-03-26 2017-06-13 衣阿华大学研究基金会 Schweinfurthin类似物
US9272016B2 (en) 2012-04-20 2016-03-01 University Of Iowa Research Foundation Methods to enhance RNAi oligonucleotide delivery to respiratory epithelial cells
JP6262723B2 (ja) 2012-05-07 2018-01-17 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ オキシステロールアナログｏｘｙ１３３は、骨発生及びヘッジホッグシグナル伝達を誘導し、脂肪生成を阻害する
RU2014148918A (ru) 2012-05-21 2016-07-10 Кеми Нутра Инк. Композиции и способы повышения выносливости и мышечной массы
WO2013177458A1 (en) 2012-05-23 2013-11-28 Chemi Nutra Compositions for increasing strength, muscle mass, and lean body mass
EP2854834A4 (en) 2012-05-30 2016-05-18 Biostrategies LC PLANT LECTINES AS AN EXCIPIENT OF RELATED MEDICINAL SUBSTANCES IN ANIMAL AND HUMAN CELLS
WO2013188882A1 (en) 2012-06-15 2013-12-19 Rutgers, The State University Of New Jersey Macromolecules for treating atherosclerosis
JP6129960B2 (ja) 2012-06-18 2017-05-17 ダート・ニューロサイエンス・（ケイマン）・リミテッド 置換ピリジンアゾロピリミジン−５−（６ｈ）−オン化合物
ES2689541T3 (es) 2012-06-19 2018-11-14 Rutgers, The State University Of New Jersey Agentes antibacterianos: derivados de aril mixopironina
EP2863910B1 (en) 2012-06-20 2020-03-11 University Of Virginia Patent Foundation Compositions and methods for regulating glucose homeostasis and insulin action
US9745331B2 (en) 2012-07-05 2017-08-29 University Of Iowa Research Foundation Therapeutic bisphosphonates
CA2876021C (en) 2012-07-10 2020-09-22 Xpd Holdings, Llc Stabilized multi-functional antioxidant compounds and methods of use
AU2013292529A1 (en) 2012-07-18 2015-02-12 Marvin J. Miller 5,5-heteroaromatic anti-infective compounds
WO2014018671A1 (en) 2012-07-24 2014-01-30 Regents Of The University Of Minnesota Therapeutic compounds for the treatment of cancer
US9839621B2 (en) 2012-07-26 2017-12-12 The William M. Yarbrough Foundation Method for treating bladder cancer
US10434082B2 (en) 2012-07-26 2019-10-08 The William M. Yarbrough Foundation Isothiocyanate functional compounds augmented with secondary antineoplastic medicaments and associated methods for treating neoplasms
WO2014018874A1 (en) 2012-07-26 2014-01-30 The William M. Yarbrough Foundation Method for treating skin cancer
US9949943B2 (en) 2012-07-26 2018-04-24 The William M. Yarbrough Foundation Method for treating neurodegenerative diseases
US10441561B2 (en) 2012-07-26 2019-10-15 The William M. Yanbrough Foundation Method for treating benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer
US10080734B2 (en) 2012-07-26 2018-09-25 The William M. Yarbrough Foundation Method for treating autism and other neurodevelopmental disorders
US10335387B2 (en) 2012-07-26 2019-07-02 The William M. Yarbrough Foundation Method for treating infectious diseases with isothiocyanate functional compounds
US10434081B2 (en) 2012-07-26 2019-10-08 The William M. Yarbrough Foundation Inhibitors of macrophage migration inhibitory factor
ES2668694T3 (es) 2012-07-27 2018-05-21 Biogen Ma Inc. Derivados de ácido 1-[7-(cis-4-metil-ciclohexiloxi)-8-trifluorometil-naftalen-2-ilmetil]-piperidin-4-carboxílico como moduladores de autotaxina (ATX) para tratar inflamaciones y trastornos autoinmunitarios
AU2013296420B2 (en) 2012-08-01 2017-12-07 Lewis And Clark Pharmaceuticals, Inc. N-alkyl 2-(disubstituted)alkynyladenosine-5-uronamides as A2A agonists
RU2652989C2 (ru) 2012-08-03 2018-05-04 Зэ Борд оф Трастиз оф зэ Юниверсити оф Иллинойс Соединения и композиции, активирующие ферменты
EP2879673B1 (en) 2012-08-06 2018-07-25 Biogen MA Inc. 1,5,6-substituted naphthalene derivatives as sphingosine 1 phosphate (S1P) receptor and/or autotaxin (ATX) modulators for treating inflammatory and autoimmune disorders
US10273234B2 (en) 2012-08-06 2019-04-30 Biogen Ma Inc. Compounds that are S1P modulating agents and/or ATX modulating agents
WO2014028025A1 (en) 2012-08-16 2014-02-20 University Of Southern California Compositions and methods for treating myotonic dystrophy type 1
DK2888010T3 (da) 2012-08-22 2021-06-28 Univ Cornell Fremgangsmåder til at hæmme fascin
US9737493B2 (en) 2012-09-07 2017-08-22 University Of Louisville Research Foundation, Inc. Compositions and methods for modulating DNMT1 inhibitor activity
US9573938B2 (en) 2012-09-11 2017-02-21 Rutgers, The State University Of New Jersey Therapeutic hydroxypyridinones, hydroxypyrimidinones and hydroxypyridazinones
WO2014043510A1 (en) 2012-09-13 2014-03-20 Chang Gung Memorial Hospital A novel pharmaceutical composition and uses thereof
EP2895202A1 (en) 2012-09-13 2015-07-22 Ben-Gurion University Of The Negev Research And Development Authority Diagnostic agents with enhanced sensitivity/specificity
SI3305285T1 (sl) 2012-09-26 2021-03-31 Aragon Pharmaceuticals, Inc. Anti-androgeni za zdravljenje proti kastraciji odpornega ne-metastatskega raka
EP2906260B1 (en) 2012-10-09 2019-06-26 Case Western Reserve University Rod-shaped plant virus nanoparticles as imaging agent platforms
US9957214B2 (en) 2012-10-10 2018-05-01 Arizona Board Of Regents On Behalf Of Arizona State University Multifunctional radical quenchers
US20140120057A1 (en) 2012-10-25 2014-05-01 Rutgers, The State University Of New Jersey Polymers and methods thereof for wound healing
US9296730B2 (en) 2012-10-26 2016-03-29 Regents Of The University Of Minnesota Aurora kinase inhibitors
WO2014070774A1 (en) 2012-10-29 2014-05-08 Southern Methodist University Methods of generating beta-lactamase resistant carbapenem compounds
BR112015010570B8 (pt) 2012-11-08 2021-04-20 Univ Rutgers agentes microbianos, composto e seu uso e composição farmacêutica
WO2014074926A1 (en) 2012-11-09 2014-05-15 Rutgers, The State University Of New Jersey Therapeutic hydroxyquinolones
CA2890905A1 (en) 2012-11-16 2014-05-22 Biocryst Pharmaceuticals, Inc. Antiviral azasugar-containing nucleosides
CN105189492A (zh) 2012-11-19 2015-12-23 萨克·W·金 麦角灵衍生物作为多巴胺受体调节剂
WO2014081756A1 (en) 2012-11-20 2014-05-30 Biogen Idec Ma Inc. S1p and/or atx modulating agents
US9850206B2 (en) 2012-11-20 2017-12-26 Biogen Ma Inc. S1P and/or ATX modulating agents
US9522131B2 (en) 2013-01-11 2016-12-20 Wisconsin Alumni Research Foundation Tannin-containing gastrointestinal formulations and methods of use
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
WO2014120764A1 (en) 2013-01-29 2014-08-07 Biogen Idec Ma Inc. S1p modulating agents
WO2014124317A1 (en) 2013-02-08 2014-08-14 Regents Of The University Of Minnesota Analgesic conjugates
JP2016518240A (ja) 2013-02-15 2016-06-23 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 粒子の官能化
EP2964618B1 (en) 2013-03-05 2019-09-04 University Of Notre Dame Du Lac Quinazolinone antibiotics
CA2895287A1 (en) 2013-03-14 2014-10-02 Dart Neuroscience, Llc Substituted naphthyridine and quinoline compounds as mao inhibitors
ES2769181T3 (es) 2013-03-14 2020-06-24 Dart Neuroscience Cayman Ltd Compuestos de piridina y de pirazina sustituidos como inhibidores de PDE4
EP2970334B1 (en) 2013-03-15 2018-05-23 Biogen MA Inc. Macrocyclic compounds as irak4 inhibitors for the treatment of inflammatory diseases
TW201446768A (zh) 2013-03-15 2014-12-16 Biogen Idec Inc S1p及/或atx調節劑
US9387250B2 (en) 2013-03-15 2016-07-12 Rutgers, The State University Of New Jersey Therapeutic compositions for bone repair
EP3246320B1 (en) 2013-03-15 2019-05-08 Rexahn Pharmaceuticals, Inc. Process for the preparation of 4-amino-1-((1s,4r,5s)-2-fluoro-4,5-dihydroxy-3- hydroxymethyl-cyclopent-2-enyl)-1h-pyrimidin-2-one
WO2014144721A2 (en) 2013-03-15 2014-09-18 Genentech, Inc. Treating th2-mediated diseases by inhibition of bromodomains
CA2911205A1 (en) 2013-05-02 2014-11-06 The Regents Of The University Of California Bone-selective osteogenic oxysterol-bone targeting agents
CA3050457C (en) 2013-05-06 2021-05-25 Kaohsiung Chang Gung Memorial Hospital A pharmaceutical composition comprising atropine and nsaid for treating myopia
US9862672B2 (en) 2013-05-29 2018-01-09 Rutgers, The State University Of New Jersey Antioxidant-based poly(anhydride-esters)
WO2014205199A2 (en) 2013-06-22 2014-12-24 Nitor Therapeutics Compositions and methods for potentiating immune response, enhancing immunotherapy, and increasing vaccine potency
US10682415B2 (en) 2013-07-22 2020-06-16 Wisconsin Alumni Research Foundation Thermogel formulation for combination drug delivery
US10117912B2 (en) 2013-08-01 2018-11-06 Regents Of The University Of Minnesota Drug delivery method
CN104341504B (zh) 2013-08-06 2017-10-24 百奥泰生物科技(广州)有限公司 双特异性抗体
EP3030241A4 (en) 2013-08-06 2019-06-19 H. Lee Moffitt Cancer Center And Research Institute, Inc. INHIBITORS OF ACK1 / TNK2.TYROSINE KINASE
US10226534B2 (en) 2013-09-12 2019-03-12 Regents Of The University Of Minnesota Semi-solid delivery systems
US9878045B2 (en) 2013-10-15 2018-01-30 Regents Of The University Of Minnesota Triorthogonal reagents for dual protein conjugation
US10624943B2 (en) 2013-11-11 2020-04-21 Kuality Herbceutics, LLC Kava derived therapeutic compounds and methods of use thereof
US9387199B2 (en) 2013-11-12 2016-07-12 University Of Virginia Patent Foundation Compositions and methods for treating clostridium infection and preventing recurrence of infection
US9339482B2 (en) 2013-11-22 2016-05-17 Regents Of The University Of Minnesota Methods to treat dysregulated blood glucose disorders
US9315523B2 (en) 2013-12-06 2016-04-19 Rutgers, The State University Of New Jersey Cyclic dinucleosides
WO2015109318A2 (en) 2014-01-17 2015-07-23 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Therapeutic methods
US9919998B2 (en) 2014-02-06 2018-03-20 Rutgers, The State University Of New Jersey Antibacterial agents: Nα-aroyl-N-aryl-phenylalaninamides
US20150231077A1 (en) 2014-02-17 2015-08-20 The Cleveland Clinic Foundation Amine passivated nanoparticles for cancer treatment and imaging
JP6691869B2 (ja) 2014-02-20 2020-05-13 コーネル ユニヴァーシティー ファシンを阻害するための化合物及び方法
US9908856B2 (en) 2014-02-26 2018-03-06 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds
WO2015130805A1 (en) 2014-02-26 2015-09-03 Arizona Board Of Regents On Behalf Of Arizona State University Dna gridiron compositions and methods
US10272055B2 (en) 2014-03-06 2019-04-30 Regents Of The University Of Minnesota Therapeutic compounds and methods
KR20230042384A (ko) 2014-03-07 2023-03-28 바이오크리스트파마슈티컬즈,인코포레이티드 인간 혈장 칼리크레인 저해제
US10197575B2 (en) 2014-03-31 2019-02-05 H. Lee Moffitt Cancer Center And Research Institute, Inc. Stabilized peptoid-peptide hybrids and uses thereof
WO2015166355A2 (en) 2014-04-18 2015-11-05 The Governors Of The University Of Alberta Targeted therapy to restore radioactive iodine transport in thyroid cancer
PL3597649T3 (pl) 2014-04-23 2022-04-04 Dart Neuroscience Llc Kompozycje zawierające podstawione związki [1,2,4]triazolo[1,5-a]pirymidyn-7-ylowe jako inhibitory pde2
EP3134406A1 (en) 2014-04-24 2017-03-01 Dart Neuroscience (Cayman) Ltd Substituted 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole and 4,5,6,7-tetrahydro-2h-pyrazolo [4,3-c]pyridine compounds as glyt1 inhibitors
US9556113B2 (en) 2014-04-29 2017-01-31 The South Dakota Board Of Regents Combination uses of dichloroacetate and oxamate, and their prodrugs, for cancer treatment
US9987299B2 (en) 2014-05-05 2018-06-05 University Of Iowa Research Foundation Methods of improving RNAi in well-differentiated airway epithelia
AR100767A1 (es) 2014-06-06 2016-11-02 Biogen Ma Inc Agentes moduladores de la atx
US10023521B2 (en) 2014-06-13 2018-07-17 Rutgers, The State University Of New Jersey Process and intermediates for preparing poly(anhydride-esters)
US10138203B2 (en) 2014-06-16 2018-11-27 Rutgers, The State University Of New Jersey Antibacterial agents
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
US9737598B2 (en) 2014-06-30 2017-08-22 Regents Of The University Of Minnesota CD200 inhibitors and methods of use thereof
WO2016007909A2 (en) 2014-07-11 2016-01-14 Biostrategies LC Materials and methods for treating disorders associated with sulfatase enzymes
US10246456B2 (en) 2014-07-18 2019-04-02 Biogen Ma Inc. IRAK4 inhibiting agents
EP3265130B1 (en) 2014-08-19 2024-05-22 Hsiri Therapeutics, LLC Antibacterial sideromycins
JP6629211B2 (ja) * 2014-08-19 2020-01-15 国立大学法人 岡山大学 免疫細胞の機能増強方法及び免疫細胞の多機能性評価方法
US10385034B2 (en) 2014-09-05 2019-08-20 The Cleveland Clinic Foundation Flavonoid IL-17A inhibitors
US9630905B2 (en) 2014-09-08 2017-04-25 Rutgers, The State University Of New Jersey Amphiphilic macromolecules and methods of use thereof
US11135178B2 (en) 2014-09-11 2021-10-05 University Of Iowa Research Foundation Thymol and carvacol for use in medicine
US10328114B2 (en) 2014-10-28 2019-06-25 University Of Iowa Research Foundation Lung injury repair compositions and methods
US10040759B2 (en) 2014-11-05 2018-08-07 Dart Neuroscience (Cayman) Ltd. Substituted azetidinyl compounds as GlyT1 inhibitors
TWI568737B (zh) 2014-11-05 2017-02-01 達特神經科學（開曼）有限責任公司 作為ｐｄｅ２抑制劑之經取代的５－甲基－［１，２，４］三唑并［１，５－ａ］嘧啶－２－胺化合物
US20190015379A1 (en) * 2014-11-10 2019-01-17 Delmar Pharmaceuticals, Inc. Use of dianhydrogalactitol and analogs and derivatives thereof, together with radiation, to treat non-small-cell carcinoma of the lung and glioblastoma multiforme and suppress proliferation of cancer stem cells
US10920195B2 (en) 2014-11-13 2021-02-16 University Of Iowa Research Foundation Methods to generate epithelial cells
DK3750545T3 (da) 2014-11-17 2024-04-22 Cellectar Biosciences Inc Phospholipidetheranaloger som cancermålrettede lægemiddelbærere
CN107406497A (zh) 2014-12-19 2017-11-28 埃博灵克斯股份有限公司 半胱氨酸连接的纳米抗体二聚体
CN107405388A (zh) 2015-01-08 2017-11-28 衣阿华大学研究基金会 用于体内关节软骨再生的方法
US10669543B2 (en) 2015-01-16 2020-06-02 University Of Iowa Research Foundation Methods to prevent or treat periodontitis or peri-implantitis
US10472340B2 (en) 2015-02-17 2019-11-12 Arizona Board Of Regents On Behalf Of Arizona State University Substituted phenothiazines as mitochondrial agents
CA2976937C (en) 2015-02-17 2023-04-04 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds
WO2016140978A1 (en) 2015-03-03 2016-09-09 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds
WO2016140979A1 (en) 2015-03-03 2016-09-09 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds
CA2978454A1 (en) 2015-03-06 2016-09-15 The Cleveland Clinic Foundation Altering steroid metabolism for treatment of steroid-dependent disease
US9926261B2 (en) 2015-03-10 2018-03-27 Rutgers, The State University Of New Jersey Bacterial efflux pump inhibitors
US9950993B2 (en) 2015-03-13 2018-04-24 Rutgers, The State University Of New Jersey Bacterial efflux pump inhibitors
US10543162B2 (en) 2015-04-10 2020-01-28 Rutgers, The State University Of New Jersey Kojic acid polymers
AU2016258123A1 (en) 2015-05-06 2018-01-04 H. Lee Moffitt Cancer Center And Research Institute, Inc. Radiotherapeutic and companion imaging agents to target MC1R
WO2016179587A1 (en) 2015-05-07 2016-11-10 Kuality Herbceutics Llc Therapeutic compounds and methods of use thereof
US20180125780A1 (en) 2015-05-15 2018-05-10 The Methodist Hospital System Implantable nanochannel delivery devices
US10188704B2 (en) 2015-05-18 2019-01-29 Arizona Board Of Regents On Behalf Of The University Of Arizona Enhanced melanoma cancer prevention by novel melanotropins
MX2017015532A (es) 2015-06-05 2018-04-30 Univ Illinois Terapia de combinacion pac-1.
TW201710503A (zh) 2015-06-12 2017-03-16 長庚醫療財團法人林口長庚紀念醫院 新穎多核苷酸、載體、醫藥組成物以及其用途
US11369569B2 (en) 2015-06-15 2022-06-28 University Of Virginia Patent Foundation Target-specific delivery of therapeutic agents
US10308663B2 (en) 2015-06-16 2019-06-04 University Of Virginia Patent Foundation Inhibitors of PTP4A3 for the treatment of cancer
US9399039B1 (en) 2015-06-30 2016-07-26 University Of South Florida Inhibitors of the FKBP51 protein from a high-throughput drug screen and methods of use
US10814006B2 (en) 2015-07-14 2020-10-27 University Of Iowa Research Foundation Fluorescent prodrugs
US10478510B2 (en) 2015-07-16 2019-11-19 Case Western Resrve University Plant virus particles for delivery of antimitotic agents
AU2016298175B2 (en) 2015-07-28 2022-01-06 University Of Iowa Research Foundation Compositions and methods of treating cancer
US10336734B2 (en) 2015-08-02 2019-07-02 H. Lee Moffitt Cancer Center And Research Institute, Inc. Inhibitors of ACK1/TNK2 tyrosine kinase
WO2017027883A1 (en) 2015-08-13 2017-02-16 San Diego State University Research Foundation Atropisomerism for increased kinase inhibitor selectivity
MA45011A (fr) 2015-09-04 2021-06-02 Janssen Pharmaceutica Nv Composé thérapeutique contre la douleur et sa synthèse
TWI796714B (zh) 2015-10-01 2023-03-21 美商百歐克斯製藥公司 人類血漿激肽釋放酶抑制劑
US10738016B2 (en) 2015-10-13 2020-08-11 H. Lee Moffitt Cancer Center And Research Institute, Inc. BRD4-kinase inhibitors as cancer therapeutics
WO2017070328A1 (en) 2015-10-20 2017-04-27 The Cleveland Clinic Foundation STIMULATION OF 11β-HSD2 EXPRESSION TO IMPROVE HORMONAL THERAPY OF STEROID-DEPENDENT DISEASE
EP3370763B1 (en) 2015-11-03 2024-04-10 Regents of the University of Minnesota Cd200 inhibitors and methods of use thereof
JP7017509B2 (ja) 2015-11-20 2022-02-08 センワ バイオサイエンシズ インコーポレイテッド がんを治療するための四環式キノロン類似体の併用療法
US9957282B2 (en) 2015-12-14 2018-05-01 Senhwa Biosciences, Inc. Crystalline forms of quinolone analogs and their salts
US9980951B2 (en) 2015-12-17 2018-05-29 University Of Iowa Research Foundation Image guided therapy for cancer
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
WO2017127430A1 (en) 2016-01-20 2017-07-27 Biogen Ma Inc. Irak4 inhibiting agents
TW202222786A (zh) 2016-02-01 2022-06-16 美商百歐克斯製藥公司 苯并吡唑化合物及其類似物
US11203576B2 (en) 2016-03-11 2021-12-21 H. Lee Moffitt Cancer Center And Research Institute, Inc. Aurora kinase and Janus kinase inhibitors for prevention of graft versus host disease
WO2017161119A1 (en) 2016-03-16 2017-09-21 H. Lee Moffitt Cancer Center & Research Institute, Inc. Small molecules against cereblon to enhance effector t cell function
AU2017238208B2 (en) 2016-03-22 2022-01-06 Regents Of The University Of Minnesota Combination for treating pain
WO2017165836A1 (en) 2016-03-24 2017-09-28 Rutgers, The State University Of New Jersey Antibacterial agents
EP3442979A4 (en) 2016-04-04 2019-12-18 Rutgers, the State University of New Jersey topoisomerase poisons
US10551384B2 (en) 2016-04-07 2020-02-04 Rutgers, The State University Of New Jersey MTOR kinase mutations and methods of use thereof
ES2946991T3 (es) 2016-04-18 2023-07-31 Gene Pool Tech Inc Aislamiento de extractos de plantas
EP3452110A4 (en) 2016-05-04 2019-12-25 H. Lee Moffitt Cancer Center And Research Institute, Inc. AGENT FOR THE MOLECULAR IMAGING AND IMMUNOTHERAPY OF CANCER DISEASES TARGETING THE DELTA OPIOID RECEPTOR
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms
KR20220120711A (ko) 2016-05-26 2022-08-30 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 폐혈관 질환 치료용 조성물 및 방법
US10899793B2 (en) 2016-05-27 2021-01-26 Regents Of The University Of Minnesota Melanocortin ligands and methods of use thereof
WO2017214296A1 (en) 2016-06-07 2017-12-14 University Of Iowa Research Foundation Junctophilin-2 fragments and uses therefor
BR112018076564A2 (pt) 2016-06-20 2019-04-02 Rutgers, The State University Of New Jersey uso de um composto de fórmula i, composições farmacêuticas, composto de fórmula i, usos de um composto ou um sal farmaceuticamente aceitável do mesmo, e compostos ou sais farmaceuticamente aceitáveis dos mesmos
AU2017281940B2 (en) 2016-06-24 2024-07-11 University Of Iowa Research Foundation Compositions and methods of treating melanoma
US10918647B2 (en) 2016-07-26 2021-02-16 University Of Southern California Selective bromodomain inhibition of fungal Bdf1
US20180037909A1 (en) 2016-08-04 2018-02-08 Chang Gung Memorial Hospital, Linkou Modified cancer cell lines and uses thereof
US11390605B2 (en) 2016-08-25 2022-07-19 Arizona Board Of Regents On Behalf Of Arizona State University Substituted pyrimidine compounds as multifunctional radical quenchers and their uses
CN109890798A (zh) 2016-08-31 2019-06-14 达特神经科学有限公司 用于治疗cns病症的羟基去甲氯胺酮衍生物
PE20190980A1 (es) 2016-10-17 2019-07-09 Genentech Inc Compuestos terapeuticos y metodos para utilizarlos
US11124541B2 (en) 2016-10-18 2021-09-21 Regents Of The University Of Minnesota Chimeric melanocortin ligands and methods of use thereof
EP3532057B1 (en) 2016-10-31 2022-12-21 Biocryst Pharmaceuticals, Inc. Prodrugs of kallikrein inhibitors
MX2019006278A (es) 2016-11-29 2019-08-21 Univ Iowa Res Found Uso de precursores de nad para mejorar la salud materna y/o salud de la descendencia.
US11071747B2 (en) 2016-11-29 2021-07-27 University Of Iowa Research Foundation Use of NAD precursors for breast enhancement
US20180194824A1 (en) 2016-12-14 2018-07-12 University Of Iowa Research Foundation Musclin peptides and methods of use thereof
UY37551A (es) 2016-12-27 2018-07-31 Biogen Ma Inc Activador de nrf2
AU2017388054B2 (en) 2016-12-28 2022-03-24 Dart Neuroscience, Llc Substituted pyrazolopyrimidinone compounds as PDE2 inhibitors
US10710957B2 (en) 2017-01-09 2020-07-14 University Of Central Florida Research Foundation, Inc. Motuporamine derivatives as antimicrobial agents and antibiotic enhancers against resistant gram-negative bacteria
US20180230105A1 (en) 2017-01-13 2018-08-16 Regents Of The University Of Minnesota Therapeutic compounds
AU2018210393A1 (en) 2017-01-20 2019-07-25 The Regents Of The University Of California Inhibitors of the N-terminal domain of the androgen receptor
US10238626B2 (en) 2017-01-23 2019-03-26 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds
US10238655B2 (en) 2017-01-23 2019-03-26 Arizona Board Of Regents On Behalf Of Arizona State University Dihydroindene and tetrahydronaphthalene compounds
US10231947B2 (en) 2017-01-23 2019-03-19 Arizona Board Of Regents On Behalf Of Arizona State University Isochroman compounds and methods of use thereof
EP3573957B1 (en) 2017-01-24 2023-04-26 Rivara, Mirko Compositions and methods for blocking sodium channels
US20190389836A1 (en) 2017-01-30 2019-12-26 Biogen Ma Inc. Nrf2 activator
US20190389830A1 (en) 2017-01-30 2019-12-26 Biogen Ma Inc. Nrf2 activator
US11168095B2 (en) 2017-02-07 2021-11-09 Biogen Ma Inc. ASK1 inhibiting agents
US11260050B2 (en) 2017-02-16 2022-03-01 United States Government As Represented By The Department Of Veterans Affairs Combination of cotinine plus antioxidant for treatment-resistant depression and correction of astrocytes functional deficit induced by depression and other neuropathological
US11938114B2 (en) 2017-03-10 2024-03-26 Rutgers, The State University Of New Jersey Bacterial efflux pump inhibitors
WO2018165612A1 (en) 2017-03-10 2018-09-13 Rutgers, The State University Of New Jersey Bacterial efflux pump inhibitors
BR112019018691A2 (pt) 2017-03-10 2020-04-07 Univ Rutgers derivados de indol como inibidores de bomba de efluxo
JOP20190233A1 (ar) 2017-04-14 2019-10-02 Biogen Ma Inc نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون
US10294264B2 (en) 2017-04-21 2019-05-21 Warsaw Orthopedic, Inc. Oxysterol-therapeutic agent derivative for bone healing
US10456401B2 (en) 2017-05-12 2019-10-29 Innovus Pharmaceuticals, Inc. Therapeutic methods and compositions
US10434106B2 (en) 2017-05-19 2019-10-08 Warsaw Orthopedic, Inc. Oxysterol-statin compounds for bone growth
JP2020520949A (ja) 2017-05-22 2020-07-16 ユニバーシティ オブ ヴァージニア パテント ファウンデーションＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｖｅｒｇｉｎｉａ Ｐａｔｅｎｔ Ｆｏｕｎｄａｔｉｏｎ 組成物、並びにミトコンドリア脱共役剤を調製及び使用する方法
WO2018218192A1 (en) 2017-05-26 2018-11-29 Rutgers, The State University Of New Jersey Bacterial efflux pump inhibitors
BR112019025097A2 (pt) 2017-06-02 2020-07-28 Merck Patent Gmbh imunoglobulinas de ligação a mmp13
TWI826376B (zh) 2017-06-02 2023-12-21 德商麥克專利有限公司 與ａｄａｍｔｓ５、ｍｍｐ１３及聚集蛋白聚醣結合的多肽
US11603401B2 (en) 2017-06-02 2023-03-14 Ablynx N.V. Aggrecan binding immunoglobulins
CA3063293A1 (en) 2017-06-02 2018-12-06 Merck Patent Gmbh Adamts binding immunoglobulins
AR112027A1 (es) 2017-06-15 2019-09-11 Biocryst Pharm Inc Inhibidores de alk 2 quinasa que contienen imidazol
EP3641783A4 (en) 2017-06-22 2021-03-10 University Of Virginia Patent Foundation PROTON-ACTIVATED NUCLEAR MEDICINE
US10934300B2 (en) 2017-06-23 2021-03-02 San Diego State University (Sdsu) Foundation Atropisomerism for enhanced kinase inhibitor selectivity
WO2019005841A1 (en) 2017-06-26 2019-01-03 Rutgers, The State University Of New Jersey THERAPEUTIC COMPOUNDS AND METHODS FOR TREATING INFECTION
MX2020000295A (es) 2017-07-12 2020-07-22 Dart Neuroscience Llc Compuestos de benzoxazol y benzofurano sustituidos como inhibidores de pde7.
CN107446050A (zh) 2017-08-11 2017-12-08 百奥泰生物科技(广州)有限公司 Trop2阳性疾病治疗的化合物及方法
WO2019046467A1 (en) 2017-08-29 2019-03-07 Rutgers, The State University Of New Jersey INDAZOLES THERAPEUTIC
EP3676380B1 (en) 2017-08-30 2022-05-18 Arizona Board of Regents on behalf of Arizona State University Rna nanostructures and methods of making and using rna nanostructures
CA3076233A1 (en) 2017-10-06 2019-04-11 Blue Therapeutics, Inc. Methods of treating acute or chronic pain
JOP20200076A1 (ar) 2017-10-16 2020-04-30 Aragon Pharmaceuticals Inc مضادات أندروجين لعلاج سرطان البروستاتا غير النقيلي المقاوم للاستئصال
CA3116829A1 (en) 2017-10-17 2019-04-25 The Methodist Hospital System Delivery devices
JP2021503481A (ja) 2017-11-17 2021-02-12 サイトジェル ファーマ リミテッド ライアビリティ カンパニー μオピオイド受容体のポリマーアゴニスト
WO2019104030A1 (en) 2017-11-21 2019-05-31 Biogen Ma Inc. Tetrahydronaphthalene derivatives useful as nrf2 activators
WO2019104285A1 (en) 2017-11-27 2019-05-31 Dart Neuroscience, Llc Substituted furanopyrimidine compounds as pde1 inhibitors
EP3716956B1 (en) 2017-11-29 2024-06-26 The Cleveland Clinic Foundation Antitumor tet2 modulating compounds
WO2019108285A1 (en) 2017-11-30 2019-06-06 Cytogel Pharma, Llc Novel analgesic pharmaceutical formulations and uses thereof
WO2019112885A1 (en) 2017-12-07 2019-06-13 The Cleveland Clinic Foundation Treatment of steroid-resistant disease using an anthocyanin and a corticosteroid
WO2019140140A1 (en) 2018-01-10 2019-07-18 Arizona Board Of Regents On Behalf Of Arizona State University Rna-nanostructured double robots and methods of use thereof
US10738093B2 (en) 2018-01-25 2020-08-11 The Hong Kong University Of Science And Technology Discovery of cationic nonribosomal peptides as Gram-negative antibiotics through global genome mining
US11685723B2 (en) 2018-02-13 2023-06-27 Rutgers, The State University Of New Jersey Antibacterial agents: O-alkyl-deuterated pyronins
KR20200131251A (ko) 2018-02-15 2020-11-23 센화 바이오사이언시즈 인코포레이티드 퀴놀론 유사체 및 이의 염, 조성물, 및 이들의 사용 방법
WO2019168921A1 (en) 2018-02-27 2019-09-06 University Of Virginia Patent Foundation Plectin-targeted liposomes/parp inhibitor in the treatment of cancer
JP7386797B2 (ja) 2018-02-28 2023-11-27 ダート・ニューロサイエンス・エルエルシー Ｎｏｐ阻害剤としての置換シクロヘキシル化合物
US11572337B2 (en) 2018-03-06 2023-02-07 Rutgers, The State University Of New Jersey Antibacterial agents: arylalkylcarboxamido phloroglucinols
US20210255170A1 (en) 2018-03-13 2021-08-19 University Of Iowa Research Foundation Inductive regeneration of the airway by transcriptional factor modulation of glandular myoepithelial stem cells
ES2942211T3 (es) 2018-03-14 2023-05-30 Biogen Ma Inc Inhibidores de la O-glucoproteína-2-acetamido-2-desoxi-3-D-glucopiranosidasa
TW202010742A (zh) 2018-04-06 2020-03-16 美商百歐克斯製藥公司 取代的苯并呋喃、苯并吡咯、苯并噻吩及結構相關的補體抑制劑
EP3781165A4 (en) 2018-04-20 2022-02-23 Virginia Tech Intellectual Properties, Inc. AMINOPYRAZINE AND RELATED COMPOUNDS AS MITOCHONDRIAL UNCOUPLERS
US20210230601A1 (en) 2018-04-27 2021-07-29 Arizona Board Of Regents On Behalf Of Arizona State University Highly knotted molecular topologies from single-stranded nucleic acids
MA52629A (fr) 2018-05-14 2021-03-24 Biogen Ma Inc Agents inhibiteurs de la tyrosine kinase de bruton
UY38278A (es) 2018-06-27 2020-01-31 Biogen Ma Inc Agentes inhibidores de ask1
SG11202100054YA (en) 2018-07-09 2021-02-25 Taiwan Liposome Co Ltd Methods to reduce complications of intra-articular steroid
PE20210184A1 (es) 2018-07-11 2021-02-02 H Lee Moffitt Cancer Ct & Res Compuestos inmunomoduladores dimericos contra mecanismos basados en cereblon
US10898460B1 (en) 2018-07-20 2021-01-26 University Of South Florida Leishmania inhibitors
WO2020028814A1 (en) 2018-08-03 2020-02-06 H. Lee Moffitt Cancer Center And Research Institute, Inc. Allosteric inhibitor of wee1 kinase
EP3837265B1 (en) 2018-08-14 2023-02-22 Biogen MA Inc. Pyridine macrocycle compounds as ask1 inhibiting agents
ES2963122T3 (es) 2018-08-14 2024-03-25 Biogen Ma Inc Agentes inhibidores de ASK1
US11332499B2 (en) 2018-08-16 2022-05-17 Regents Of The University Of Minnesota Cyclic peptides and methods of use thereof
EP3849994A1 (en) 2018-09-13 2021-07-21 Minneamrita Therapeutics, LLC Triptolide and prodrugs thereof for use in methods to treat fibrosis, nash, and nafld
UY38376A (es) 2018-09-19 2020-04-30 Biogen Ma Inc Inhibidores de o-glicoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa
JP7476214B2 (ja) 2018-10-15 2024-04-30 バイオジェン・エムエイ・インコーポレイテッド ブルトン型チロシンキナーゼ阻害剤の結晶多形
JP2022503696A (ja) 2018-10-17 2022-01-12 サンステイト バイオサイエンシーズ， エルエルシー 治療効果を高めるために単一タンパク質でカプセル化された医薬品
US20220002238A1 (en) 2018-11-07 2022-01-06 Regents Of The University Of Minnesota Analgesic and anti-addictive compositions for treatment of chronic pain and opioid addiction
US20210398673A1 (en) 2018-11-09 2021-12-23 The University Of Rochester Methods and systems for treating cancer based on response prediction using light scattering technology
CA3120970A1 (en) 2018-11-26 2020-06-04 Denali Therapeutics Inc. Methods for treating dysregulated lipid metabolism
UY38498A (es) 2018-12-05 2020-07-31 Biogen Ma Inc Inhibidores de o-glucoproteina-2- acetamido-2-desoxi-3-d-glucopiranosidasa de morfolinilo , piperazinilo , oxazepanilo y diazepanilo
CA3126156A1 (en) 2019-01-14 2020-07-23 Regents Of The University Of Minnesota Cd200ar ligands for cancer immunotherapy
EP3921316A1 (en) 2019-02-04 2021-12-15 Biogen MA Inc. Bicyclic ether o-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
MA55203A (fr) 2019-03-08 2022-01-12 Biogen Ma Inc Inhibiteurs d'azétidinyl 0-glyc0pr0téin-2-acétamid0-2-désoxy-3-d-gluc0pyran0sidase
WO2020225779A1 (en) 2019-05-09 2020-11-12 Istituto Pasteur Italia - Fondazione Cenci Bolognetti Rig-i agonists for cancer treatment and immunotherapy
MA55964A (fr) 2019-05-15 2022-03-23 Biogen Ma Inc Agents inhibiteurs de la tyrosine kinase de bruton
US20220241214A1 (en) 2019-06-20 2022-08-04 University Of Iowa Research Foundation Nanoparticles comprising quinone w methides and compositions for use
US20220411398A1 (en) 2019-06-24 2022-12-29 University Of Iowa Research Foundation Jnk inhibitors as anticancer agents
CN114206839A (zh) 2019-08-06 2022-03-18 拜奥克里斯特制药公司 血浆激肽释放酶抑制剂的生产规模合成
BR112022006739B1 (pt) 2019-10-10 2024-01-23 Cellectar Biosciences, Inc Conjugados fosfolipídio-flavagina e métodos de uso do mesmo para terapia direcionada a câncer
CN115279756A (zh) 2019-10-25 2022-11-01 埃克森特治疗公司 Mettl3调节剂
CN114929709A (zh) 2019-10-29 2022-08-19 比奥根Ma公司 螺环o-糖蛋白-2-乙酰胺基-2-脱氧-3-d-吡喃葡萄糖苷酶抑制剂
WO2021087086A1 (en) 2019-10-30 2021-05-06 Biogen Ma Inc. Condensed pyridazine or pyrimidine as btk inhibitors
JP2023501236A (ja) 2019-10-30 2023-01-18 バイオジェン・エムエイ・インコーポレイテッド ブルトン型チロシンキナーゼに対する阻害剤としての縮合型二複素環
US20230121818A1 (en) 2019-12-23 2023-04-20 Biogen Ma Inc. Btk inhibitors
US20230053688A1 (en) 2020-01-10 2023-02-23 Cornell University Methods to alter latency in ebv+ malignancies
CA3183957A1 (en) 2020-05-18 2021-11-25 Salk Institute For Biological Studies Chromen-4-one derivatives, such as e.g. flavones, for use as ck2 inhibitors for the treatment of neuroinflammation
CN116056693A (zh) 2020-07-10 2023-05-02 长庚医疗财团法人林口长庚纪念医院 β-1肾上腺素受体拮抗剂用于制备减少表皮生长因子受体抑制剂诱导的上皮细胞损伤以及抑制癌细胞的组合物的用途
US11529335B2 (en) 2020-07-31 2022-12-20 University Of Iowa Research Foundation Compositions and methods for treating cancer
UY39370A (es) 2020-08-07 2022-02-25 Biogen Ma Inc Inhibidores de la btk
WO2022051326A1 (en) 2020-09-02 2022-03-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Lzk‑targeting degraders and methods of use
JP2023546549A (ja) 2020-10-14 2023-11-02 アクセント・セラピューティクス・インコーポレイテッド Ｍｅｔｔｌ３モジュレーター
WO2022150446A1 (en) 2021-01-07 2022-07-14 Biogen Ma Inc. Tyk2 inhibitors
WO2022178437A1 (en) 2021-02-22 2022-08-25 Regents Of The University Of Minnesota Immunomodulators and immunomodulator conjugates
TWI796023B (zh) 2021-03-10 2023-03-11 長庚醫療財團法人 藥物組合物及其用途
EP4313023A1 (en) 2021-04-02 2024-02-07 Biogen MA Inc. Combination treatment methods of multiple sclerosis
US11780828B2 (en) 2021-05-04 2023-10-10 Regents Of The University Of Minnesota Contraceptive compounds and methods
AU2022268977A1 (en) 2021-05-05 2023-11-30 Biogen Ma Inc. Compounds for targeting degradation of bruton's tyrosine kinase
WO2022271861A1 (en) 2021-06-22 2022-12-29 Dana-Farber Cancer Institute, Inc. (1h-pyrrolo[2,3-b]pyridin-1-yl)pyrimidin-2-yl-amino-phenyl--acrylamide inhibitors of egfr for use in the treatment of brain tumors
WO2022271951A1 (en) 2021-06-23 2022-12-29 University Of Iowa Research Foundation Sustained release formulations comprising a selective androgen receptor modulator
UY39844A (es) 2021-07-07 2023-01-31 Biogen Ma Inc Compuestos para la degradación selectiva de las proteínas irak4
WO2023283372A1 (en) 2021-07-07 2023-01-12 Biogen Ma Inc. Compounds for targeting degradation of irak4 proteins
EP4395899A1 (en) 2021-09-01 2024-07-10 The United States of America, as represented by the Secretary, Department of Health and Human Services Mixed lineage kinase inhibitors and methods of use
WO2023081237A1 (en) 2021-11-03 2023-05-11 Regents Of The University Of Minnesota Toll-like receptor agonists and antagonists and uses thereof
WO2023086521A1 (en) 2021-11-10 2023-05-19 Biogen Ma Inc. Btk inhibitors
WO2023086575A1 (en) 2021-11-12 2023-05-19 Biogen Ma Inc. Btk inhibitors
AU2022391744A1 (en) 2021-11-18 2024-06-27 Cornell University Microrna-dependent mrna switches for tissue-specific mrna-based therapies
WO2023130022A2 (en) 2021-12-29 2023-07-06 University Of Iowa Research Foundation Cystatin rna compositions for tissue engineering
WO2023220049A1 (en) 2022-05-10 2023-11-16 Biogen Ma Inc. Crystalline polymorphs of n-methyl-n-((1s,3s)-3-methyl-3-((6-(1-methyl-1h-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)cyclobutyl)acrylamide
WO2023220046A1 (en) 2022-05-10 2023-11-16 Biogen Ma Inc. Tyk2 inhibitors
WO2024006493A1 (en) 2022-07-01 2024-01-04 Biogen Ma Inc. Tyk2 inhibitors
WO2024006977A1 (en) 2022-07-01 2024-01-04 University Of Southern California Analgesic delta opioid receptor bitopic ligands
WO2024009283A1 (en) 2022-07-07 2024-01-11 University Of Southern California At2 antagonists for non-addictive pain relief
TW202409024A (zh) 2022-07-08 2024-03-01 美商愛克堤歐生物科學公司 治療性化合物及方法
WO2024100093A1 (en) 2022-11-09 2024-05-16 Merck Patent Gmbh Toll-like receptor 7 agonists as immune-stimulators to elicit the innate antitumor immunity
WO2024112932A1 (en) 2022-11-23 2024-05-30 Regents Of The University Of Minnesota Immunomodulators and immunomodulator conjugates
WO2024124023A2 (en) 2022-12-07 2024-06-13 Rutgers, The State University Of New Jersey Carbonic anhydrase enzyme inhibitors and methods of use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4148885A (en) * 1973-09-25 1979-04-10 Institut Merieux Immunostimulant medicine
US4594238A (en) * 1980-08-08 1986-06-10 Regents Of University Of Minnesota Inhibition of undesired effect of platinum compounds
US4645661A (en) * 1984-06-29 1987-02-24 St. Jude Children's Research Hospital Method for alleviating cisplatin-induced nephrotoxicity and dithiocarbamate compounds for effecting same

Also Published As

Publication number Publication date
AU4335589A (en) 1990-04-02
US4938949A (en) 1990-07-03
AU623184B2 (en) 1992-05-07
DK44791A (da) 1991-05-10
JPH04500676A (ja) 1992-02-06
WO1990002550A1 (en) 1990-03-22
EP0433393A4 (en) 1992-01-15
NZ230622A (en) 1991-09-25
DE68921760D1 (de) 1995-04-20
EP0433393A1 (en) 1991-06-26
EP0433393B1 (en) 1995-03-15
ATE119771T1 (de) 1995-04-15

Similar Documents

Publication Publication Date Title
DK44791A (da) Behandling af beskadiget knoglemarv
EP0139535B1 (en) Compositions for combatting toxaemia
DK0379979T3 (da)
DE69223914D1 (de) 4-substituierte-2-Deoxy-2,3-Didehydro Alpha-D-Neuraminsäure antivirale Derivate
DE69306505D1 (de) Trifluormethylketon Peptid Derivate mit HLE-inhibierende Aktivität, deren Herstellung und pharmazeutischen Zusammensetzungen
NO884391D0 (no) Legemiddel-lipidsystemer med lav toksisitet.
DE69322251D1 (de) Medizinische zusammensetzung
CA2003289A1 (en) Use of trifluoromethylphenyl-tetrahydropyridines for the preparation of pharmaceutical compositions useful for the treatment of anxiety and anxio-depressive disorders
NO155932C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive erytromycin-derivater.
KR910004191A (ko) 신질환치료제
DK0476066T3 (da) Antiviralt præparat indeholdende 3-azido-2,3-dideoxy-5-methylcytidin
EP0298192A1 (en) Stable, injectable solutions of vincristine salts
KR960034200A (ko) 항편두통성 인돌릴알킬-피리딘일 및 피리미딘일피페라진의 1,2,5-티아디아졸 유도체
KR890008136A (ko) 항균성 9-데옥소-9a-알릴 및 프로파길-9a-아자-9a-호모에리트로 마이신 A 유도체
US3051626A (en) Aminoiminomethane sulfinic acid tumorinhibitory process and pharmaceutical composition
KR880004810A (ko) 소화성 궤양 치료제
KR890003372A (ko) 피리미도[2,1-b] 벤조티아졸 유도체로된 동맥경화 치료의약
KR19990063735A (ko) 1,2,4-벤조트리아진 옥사이드 제제
KR910000785A (ko) 9-r-아자사이클릭 에리트로마이신 항생제
KR100190869B1 (ko) 아목시실린 및 클라부란산을 포함하여 구성되는 수의학적 조성물 및 그를 사용한 치료방법
ES2169117T3 (es) Uso de derivados de 2-aminopurina en el tratamiento y profilaxis de la infeccion por el virus 7 del herpes humano.
ATE21908T1 (de) Derivate von 1,4-diaminocyclitol, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
RU93004873A (ru) Трициклические бензодиазепиновые производные, способ их получения, фармацевтическая композиция и способ лечения
KR950703966A (ko) 협착증 억제를 위한 미코페놀산, 미코페놀레이트 모페틸 또는 이의 유도체의 용도(Use of mycophenolic acid, mycophenolate mofetil or derivate thereof to inhibit stenosis)
ES2169116T3 (es) Uso de los derivados de 2-amino purina en el tratamiento y profilaxis del virus 6 del herpes humano.